MicroPharm has received a £0.8m grant from the Technology Strategy Board (TSB) to develop its C. difficile treatment. The drug developer, which is headquartered at Newcastle Emlyn in Carmarthenshire, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果